Transcatheter Aortic Valve Implantation With Sapien 3 Transcatheter Heart Valve for Pure Aortic Regurgitation

NCT04671758 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2020-12-17

No results posted yet for this study

Summary

The hypothesis is that TAVI using a SAPIEN 3 THV is feasible and safe for the treatment of pure AR.

Conditions

  • Pure Aortic Regurgitation

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Dominique Himbert, MD · Assistance Publique - Hôpitaux de Paris

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-01
Primary Completion
2021-12-31
Completion
2022-03-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04671758 on ClinicalTrials.gov